This phase I trial is to find out the best dose, possible benefits and/or side effects of lenalidomide when added to nivolumab and the usual drugs (rituximab and methotrexate) in patients with primary central nervous system (CNS) lymphoma.
You will be given intravenous induction chemotherapy every 2 weeks for twelve weeks overall. Each chemotherapy treatment during this induction period includes an overnight hospital stay. During the maintenance period treatment, you will take the study drug lenalidomide, and track your usage in a drug diary, and perhaps an infusion of the study drug nivoumab every 4 weeks for up to twelve times. Study procedures include regular bloods draws, and three lumbar punctures before and during treatment, to to better understand how the new agents - nivolumab and lenalidomide - affect the central nervous system.
You or your insurance provider will not have to pay for the study drugs lenalidomide and/or nivolumab while you take part in this study
Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Christopher Dittus
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
22-3183